J. Bean

A systems view of epithelial–mesenchymal transition signaling states

Stuart Thomson, James Bean, Sean L. Seymour, 2010, Clinical & Experimental Metastasis.

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

William Pao, Stephen Broderick, Lu Wang, 2007, Proceedings of the National Academy of Sciences.

Intestinal microbiome composition influences the peripheral inflammatory state during treatment of human tuberculosis

M. Glickman, Y. Taur, V. Bucci, 2020 .

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma

M. Ladanyi, W. Pao, Gregory Riely, 2008, Clinical Cancer Research.

Computational and synthetic studies towards improving rescinnamine as an inducer of MSH2-dependent apoptosis in cancer treatment

F. Salsbury, J. Bean, A. Vasilyeva, 2013, Molecular cancer biology.

Improving rescinnamine as an inducer of MSH 2-dependent apoptosis in cancer treatment

F. Salsbury, J. Bean, A. Vasilyeva, 2013 .

Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models

J. Bean, J. Haley, E. Ullman, 2014, Front. Oncol..

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.

W. Pao, J. Shih, Yeun-Chung Chang, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.